Glucagon antagonists/inverse agonists
US6503949B1 · kind B1 · utility
35Cited by
4References
56Claims
0Family size
Assignee
Inventors
Key dates
| Filing date | May 16, 2000 |
| Grant date | Jan 7, 2003 |
| Priority date | — |
| Expiry date | May 16, 2020 |
Classification
- Technology area (CPC C)Chemistry; Metallurgy
- CPC primaryC07C2603/94
- WIPO fieldOrganic fine chemistry
- WIPO sectorChemistry
Abstract
Disclosed is a novel class of compounds of formula (I) wherein V, A, Y, Z, R1, E, X and D are as defined in the specification. These compounds act to antagonize the action of the glucagon hormone on the glucagon receptor. Owing to their antagonizing effect of the glucagon receptor, the compounds are suitable for treating or preventing glucagon-mediated conditions and diseases such as hyperglycemia, Type 1 diabetes, Type 2 diabetes and obesity.
Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.